Key facts
- This page summarizes AGENUS INC's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Oct 2023, 17:49.
AGENUS INC - 12 Oct 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- INKT
- Reported as of
- 12 Oct 2023
- Net transaction value
- +$25,270
- SEC form
- 4
- Accepted by SEC
- 16 Oct 2023, 17:49:39 UTC
- Prior SEC filing
- 06 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Christine Klaskin, Vice President, Finance
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
AGENUS INC filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 16 Oct 2023.
Change
- Previous filing in this sequence was filed on 06 Oct 2023.
- Current net transaction value: +$25,270.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INKT
transaction
Common Stock
Purchase
- Transaction value
- $3,488
- Shares
- +3,173
- Change %
- +0.01%
- Price
- $1.10
- Shares after
- 21,753,061
- Date
- 12 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
INKT
transaction
Common Stock
Purchase
- Transaction value
- $21,310
- Shares
- +19,373
- Change %
- +0.09%
- Price
- $1.10
- Shares after
- 21,772,434
- Date
- 13 Oct 2023
- Ownership
- Direct
- Footnotes
- F2, F3
INKT
transaction
Common Stock
Purchase
- Transaction value
- $472
- Shares
- +429
- Change %
- +0%
- Price
- $1.10
- Shares after
- 21,772,863
- Date
- 16 Oct 2023
- Ownership
- Direct
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Open market purchases reported on this line occurred at a weighted average price of $1.0994 (range of $1.08 to $1.10).
Footnote F2
Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
Footnote F3
Open market purchases reported on this line occurred at a price of $1.10.
Footnote F4
Open market purchases reported on this line occurred at a weighted average price of $1.0992 (range of $1.09 to $1.10).